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Abstract
Background Dalfampridine extended-release tablets (dal-
fampridine-ER; in Europe, prolonged-release fampridine,
and elsewhere, fampridine modified or fampridine sustained
release), 10 mg twice daily, are available for the treatment
of improvement of walking in patients with multiple scle-
rosis, as demonstrated by an increase in walking speed. On-
drug patient perspectives and experiences are valuable to
understand and manage this patient population.
Objective The objective of this study was to examine
perspectives and experiences of patients receiving
dalfampridine-ER in a real-world setting.
Methods Step Together, an ongoing program that cap-
tures real-world patient experience with dalfampridine-ER
treatment, consists of a survey administered at baseline
(before dalfampridine-ER initiation) and at 30 (first follow-
up) and 60 days (second follow-up) after initiation. The
survey includes modified versions of the 12-item Multiple
Sclerosis Walking Scale (mMSWS-12) and the Sheehan
Disability Scale (mSDS) to assess walking ability and
functional impairment, respectively.
Results As of September 2013, 2,248 patients participated
in the baseline survey and 522 completed both follow-up
surveys (completers). Among the completers, improvements
in walking ability and function relative to baseline were
significant at both follow-ups as measured by mMSWS-12
and mSDS scores, respectively. Notably, 69–74 % of
completers at both follow-ups had improved mMSWS-12
scores, with scores greater than the range considered to be
minimally clinically significant. Patients who completed the
program expressed satisfaction with overall dalfampridine-
ER treatment, and 69 % indicated that the survey would help
them communicate better with their healthcare providers.
Conclusion Results highlight the utility of patient-repor-
ted outcomes in the assessment of patient perspective and
experience, providing a useful supplement to traditional
objective measures used in clinical studies.
Key Points for Decision Makers
Step Together, a patient feedback program, provides
insight into the real-world perspectives and treatment
experiences ofpatientswhohave receiveddalfampridine
extended-release tablets (dalfampridine-ER) for
multiple sclerosis (MS)-related walking impairment.
Perceived improvements in walking after
dalfampridine-ER treatment were statistically and
clinically significant relative to baseline
measurements. Perceived improvements were also
reported on the impact of MS symptoms on work,
social life, and family life activities.
Patients who completed the program reported
satisfaction with overall dalfampridine-ER
treatment, and 69 % of those who completed
expressed that the survey would allow them to better
communicate with their healthcare providers.
Electronic supplementary material The online version of this
article (doi:10.1007/s40271-014-0102-z) contains supplementary
material, which is available to authorized users.
H. Crayton (&)
MS Center of Greater Washington, 8320 Old Courthouse Road,
Suite 400, Vienna, VA 22181, USA
e-mail: msdoc1@hotmail.com
M. Sidovar  A. Guo
Acorda Therapeutics, Inc., Ardsley, NY, USA
S. Wulf




People with multiple sclerosis (MS) consider walking
impairment to be the most challenging aspect of their
disease; walking impairment has been reported to sub-
stantially reduce independence in activities of daily living,
including the ability to participate in physical and social
activities [1]. In a survey conducted in 3,670 people with
MS, perception of slower walking speed was consistently
associated with progressively reduced quality of life,
especially for those domains related to physical function,
even after adjustment for demographics and other MS-
related disabilities and symptomatology [2].
While disease-modifying therapies (DMTs) continue to
be the mainstay of MS treatment for reducing relapses and
slowing disease progression, an integrative approach to
patient management that targets symptoms and disabilities
has increasingly been emphasized [3–5]. Treatment strat-
egies for walking impairment have been limited primarily
to non-pharmacologic therapies, such as exercise and
rehabilitation, which may provide short-term benefits [6,
7]. In 2010, dalfampridine extended-release tablets (dal-
fampridine-ER; in Europe, prolonged-release fampridine,
and elsewhere, fampridine modified or fampridine sus-
tained release), 10 mg twice daily, were approved by the
US Food and Drug Administration for the treatment of
improvement of walking in patients with MS, as measured
by an increase in walking speed [8].
Two phase III trials, MS-F203 [9] and MS-F204 [10],
demonstrated that dalfampridine-ER improved walking
speed in a proportion of patients with MS. In a pooled
analysis of these trials, improvement from baseline in
walking speed, as measured by the timed 25-foot walk
(T25FW) was 25.0 % for those who responded to dal-
fampridine-ER treatment compared with 7.0 % for dal-
fampridine-ER non-responders and 6.5 % for the placebo
group [11]. In addition to the T25FW, which is a clinician-
assessed measure for assessment of treatment effect in
walking, patient-rated improvement in walking was also
demonstrated using the 12-item Multiple Sclerosis Walk-
ing Scale (MSWS-12) [12]. Dalfampridine-ER timed-walk
responders reported a change of -6.61 points on the
MSWS-12 compared with -0.32 points for non-responders
and 0.69 points for placebo-treated patients [11]; a 4- to
6-point change in MSWS-12 score has been considered to
be minimally clinically meaningful [13].
Few studies have been published on patient-reported
outcomes of dalfampridine-ER in the real-world setting. In
one study of 39 veterans followed for up to 1 year, sub-
stantial improvements in self-perceived walking ability
were observed as early as 6–8 weeks after starting treatment
and were maintained for up to 1 year of follow-up [14].
In another study, a case series of 67 patients followed
over a 6-month period showed that clinical benefit varied
among patients, with a greater proportion showing benefit
on self-reported measures than on clinician-assessed
measures [15]. These results suggest that patient-reported
outcomes, such as the MSWS-12, may also be useful for
assessing improvement in walking in real-world clinical
practice.
Despite the association between impaired walking and
worsening of quality of life [3], there is often a lack of
communication regarding issues with walking between
patients and their healthcare providers (HCPs). In a survey
of 1,011 MS patients conducted by the North American
Research Committee on MS, 39 % of patients reported that
they had rarely or never spoken with their HCPs about MS-
related walking problems, regardless of how frequently
they had experienced these issues [1].
The Step Together program was initiated with the
objective of capturing real-world patient experience on
dalfampridine-ER treatment with perspectives on walking,
and to provide feedback to the patients’ HCPs to facilitate
communication. Patient feedback programs such as this
may also provide value to other healthcare stakeholders,
since real-world patient experience and perspectives are
becoming important medical-care outcomes in the health-
care decision-making process [16].
2 Methods
The Step Together program, initiated in January 2012 and
currently active, is available to patients with MS for whom
dalfampridine-ER has been prescribed for the treatment of
walking impairment. The current analysis comprises data
collected through to 2 September 2013, unless otherwise
noted. As of this date, a total of 3,094 HCPs from
throughout the USA participated in this program and were
engaged in identifying MS patients from their practices
who were prescribed dalfampridine-ER for the first time,
regardless of insurance coverage. To be eligible for
inclusion in the program, adult patients prescribed dal-
fampridine-ER were required to receive their medication
through a single specialty pharmacy. There were no other
inclusion or exclusion criteria. Patient participation was
entirely voluntary and those who wished to participate
were provided the opportunity by the specialty pharmacy at
the time of first filling of the prescription. For enrollment,
patients were required to call a toll-free telephone number
and upon providing consent were included in the program.
A full clinical trial informed consent was not required as
this was not a clinical trial. Institutional Review Board
approval or exemption was not sought for this patient/
caregiver survey study. The primary purpose of the survey
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study was for market research wherein participation by the
patients was voluntary and patients were prescribed dal-
fampridine-ER according to their physician’s clinical
judgment and practice guidelines independent of the sur-
vey. No changes were made to patient treatment due to
participation in this survey.
The program consists of a survey that was designed by
physician and research staff at Physician Interactive, the
survey administrator. The survey consists of questions on
patient experience with dalfampridine-ER for administra-
tion at three timepoints: baseline (prior to initiating dal-
fampridine-ER) and at 30 (first follow-up) and 60 days
(second follow-up) after initiating treatment. At each fol-
low-up visit, patients were asked if they were still taking
dalfampridine-ER; those who were not on the drug were
excused from taking that follow-up survey. After the
baseline survey, patients could participate in the follow-up
surveys either by telephone, via an interactive voice-
response system, or through the Internet. Following com-
pletion of each survey, patients were given a pedometer, a
neck cooler, and a US$10 iTunes gift card, respectively; no
incentive was provided for HCP participation. The survey
responses were shared as customized patient-specific
reports with each patient and their HCP.
For the purpose of this analysis, all patient responses
were de-identified and aggregated for evaluation of patient-
reported outcomes and satisfaction with dalfampridine-ER.
The survey (Electronic Supplementary Material Online
Resource 1) included demographics, baseline clinical
characteristics, utilization of and satisfaction with dalfam-
pridine-ER, and patient-reported outcomes on walking and
overall function. The two patient-reported measures used
were the MSWS-12 [12] and the Sheehan Disability Scale
(SDS) [17], both of which were adapted for use in the
current survey.
The MSWS-12 is a disease-specific questionnaire con-
sisting of 12 items that assess the impact of MS on walking
over a recall period of 2 weeks using a Likert scale
(1 = not at all, 5 = extremely) [12], with an estimated 4-
to 6-point change identified as the minimal clinically
important difference (MCID) based on data from both the
phase III trials and community-based studies [13]. A neg-
ative change in MSWS-12 score indicates an improvement.
Although all 12 items from the MSWS-12 version 1 were
used, the scale was modified (mMSWS-12) for the Step
Together program. These modifications consisted of
removal of the 2-week recall period, and administration of
the scale via either a web- or telephone-based system.
Scores on the individual items were summed and trans-
formed to a 0–100 scale, with higher scores indicating
greater impact of disease on walking. The scores were
stratified by quintiles, since no cut-off values currently
exist for defining levels of severity. The total mean score
was considered an indicator of the overall impact of MS on
walking. The proportions of patients who had achieved
improvements from baseline that met the MCID thresholds
of 4 and 6 points were also calculated.
The SDS is a measure that assesses functional impair-
ment in three interrelated domains [17]. Using a 0–10
visual analog response (0 = not at all, 10 = extremely),
the scale generates four scores: a work disability score, a
social life disability score, a family life disability score,
and a total score. In the current survey, the SDS was
modified to include three questions relating to the impact of
MS symptoms on work, social life, and daily activities (i.e.,
‘‘How much have your MS symptoms disrupted your
normal work activities; social activities; daily activities?’’).
Additional modifications included truncating the responses
to a 1–9 scale (1 = not at all disrupted, 9 = completely
disrupted) to allow stratification of levels of disruption as
low (1–3), moderate (4–6), and high (7–9).
To assess overall satisfaction with dalfampridine-ER
treatment and patient perception of improvement in walk-
ing, the following two questions were asked: ‘‘Overall, how
satisfied are you so far with dalfampridine-ER?’’ and ‘‘How
satisfied have you been with how dalfampridine-ER has
helped with your walking?’’ The responses were scored on
a 1–9 scale with 1 as ‘‘not satisfied’’ and 9 representing
‘‘very satisfied.’’
To capture information on the reasons for not com-
pleting the survey, business reply cards (BRCs) were sent
during the last 2 weeks of May 2013 to patients who had
missed multiple reminders and didn’t complete the follow-
up surveys. This component of the survey reflects data
collected through to 5 August 2013. The BRCs included
two questions, one on current and intended use of dal-
fampridine-ER (i.e., ‘‘Describe your dalfampridine-ER
extended release tablet use’’) and the other on the reason
for not having completed the follow-up (i.e., ‘‘Why didn’t
you take your follow-up survey in the Step Together
Program?’’).
Results from the first and second follow-up periods were
compared with those of baseline using the Wilcoxon
signed-rank test; p values\0.05 were considered statisti-
cally significant. Descriptive statistics [N, mean, standard
deviation (SD)] were calculated for continuous variables,
and frequencies and percentages were reported for cate-
gorical variables. To examine for associations between
improvements in mMSWS-12 score and improvements in
normal work and normal social and daily activities,
Spearman rank-order correlation coefficients (rs) were
used. Coefficient values of 0.1, 0.3, and 0.5 were inter-
preted as small, moderate, and high, respectively. All
analyses were performed using the Statistical Package for
Social Sciences (SPSS, SPSS V 10.0.2 SPSS Inc, Chi-
cago, IL) [18].
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3 Results
3.1 Patient Demographics and Clinical Characteristics
As of September 2013, there were 2,324 dalfampridine-
ER-naı¨ve patients enrolled in the program. Of the enrol-
lees, 2,248 (96.7 %) patients participated in the baseline
survey (baseline group), 402 (17.3 %) completed the first
follow-up but not the second follow-up, and 522 (22.5 %)
completed both follow-up surveys (completer group). On
average, patients took 42.0 ± 18.5 days to complete the
first follow-up and 86.0 ± 53.4 days for the second follow-
up after the baseline survey. Demographics and clinical
characteristics were similar between the baseline and
completer groups (Table 1): 73 % female, mean age
50 years, 42 % had MS[10 years; approximately 80 % of
patients were using DMTs, of which the most common
were glatiramer acetate (*22 %) and interferon-b-1a
(*21 %).
3.2 Patient Perspectives of Treatment Outcome
3.2.1 Improvement in Walking
Among the 522 completers, the mean ± SD total baseline
score for the mMSWS-12 was 67.1 ± 21.1. After initiation
of treatment, perceived improvements in walking ability
were reported by patients, as indicated by mean total scores
of 53.1 ± 23.7 and 50.4 ± 24.7 at the first and second
follow-ups, respectively (Fig. 1a). These scores were sig-
nificantly lower than those at baseline (p\ 0.001) at both
timepoints, and represent changes of -14.0 and -16.7 at
the first and second follow-ups, respectively, indicating
improvement. Evaluation of patients who achieved the
MCID showed that 74 % of patients reported improvement
of C4-points during each of the two follow-up periods,
while 68 % reported improvement of C6-points at the first
follow-up and 70 % at the second follow-up period
(Fig. 1b). Comparable results with those of patients who
completed both follow-ups were reported by those patients
who completed the first follow-up but not the second
(n = 402): mean total mMSWS-12 scores at baseline and
at first follow-up were 66.5 and 54.5, respectively; 71 and
65 % reported improvements of C4-point and 6-point
changes from baseline, respectively.
To determine whether the patient-reported improvement
varied with severity of walking impairment at baseline,
completers were stratified by quintiles of baseline
mMSWS-12 scores (Fig. 1c). The majority of patients
([70 %) reported C4-point and C6-point changes from
baseline in all quintiles except for the first (lowest severity
of illness), where 64 % reported a[4-point change and
51 % reported a[6-point change (Fig. 1c).
3.2.2 Improvement in Functional Impairment
At baseline, mean ± SD scores on modified SDS (mSDS)
domains were 6.4 ± 2.4 for normal work activities,
6.1 ± 2.2 for social activities, and 6.1 ± 2.0 for daily
activities (Fig. 2a). At the first follow-up period, patients
reported significantly less disruption relative to baseline on
all mSDS domains (p\ 0.001): a reduction of 23, 20, and
20 % for impact on normal work activities, social activi-
ties, and daily activities, respectively (Fig. 2a). Small
additional improvements were observed at the second fol-
low-up, with mean scores also significantly lower
(p\ 0.001) than baseline by 26, 23, and 25 % for the
respective domains (Fig. 2a). Comparable improvement
with that of those who completed both follow-ups was
reported by those patients who completed the first follow-
up only.
At baseline, approximately 50 % of completers reported
scores of 7–9 on all mSDS domains, consistent with a high
Table 1 Demographic and clinical characteristics of enrolled
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Disease modifying therapy, %
None 19 20
Interferon beta-1a 21 22
Interferon beta-1b 6 7






66.0 ± 21.8 67.1 ± 21.1
MS multiple sclerosis, MSWS-12 12-item Multiple Sclerosis Walking
Scale, N sample size, SD standard deviation
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level of disruption of daily activities (Fig. 2b). Following
treatment with dalfampridine-ER, the proportion of
completers who reported high levels of disruption was
progressively lower at each follow-up (Fig. 2b), with
baseline percentages reduced by approximately half at the
second follow-up period (Fig. 2b).
3.2.3 Improvement in Walking Versus Improvement
in Functional Impairment
Among the completers, change from baseline in total
mMSWS-12 scores at both follow-ups were positively and
significantly associated with corresponding changes in
mSDS domains, indicating that improvement in walking
was associated with improvement in functional impair-
ment. At the first follow-up, statistically significant
and moderate associations were observed between
improvement in walking and improvement in normal work
activities (p\ 0.001, rs = 0.35), normal social activities
(p\ 0.001, rs = 0.44), and normal daily activities
(p\ 0.001, rs = 0.46). At the second follow-up,
associations were moderate to strong between improve-
ment in walking and functional domains: normal work
(p\ 0.001, rs = 0.48), and social (p\ 0.001, rs = 0.51)
and daily activities (p\ 0.001, rs = 0.55).
3.3 Patient Satisfaction and Communication
with Healthcare Providers
Most patients (69 %) who completed all three surveys
expressed that participating in the survey would help them
communicate better with their HCP, 4 % thought it would
not help communication, and 27 % were unsure.
Completers expressed moderate satisfaction with dal-
fampridine-ER on walking and moderate satisfaction
overall with treatment: mean ± SD satisfaction scores
were 5.7 ± 2.5 and 5.9 ± 2.4, respectively, on a scale of
1–9. There were no statistically significant differences
among quintiles of baseline walking impairment
(mMSWS-12 scores) for satisfaction with walking or with
overall treatment (Fig. 3). However, overall satisfaction
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Fig. 1 Patient-reported walking ability as measured by mMSWS in
the completers (n = 522). a Mean ± SD score on the mMSWS-12.
b Proportion of completers achieving C4- and C6-point changes from
baseline. c Proportion of completers achieving C4- and C6-point
changes from baseline stratified by baseline mMSWS-12 score
quintiles. mMSWS-12 modified 12-item Multiple Sclerosis Walking
Scale, SD standard deviation
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(quintiles 1–3) relative to those with greater impairment
(quintiles 4 and 5). Additionally, for each quintile of
baseline illness severity, overall treatment satisfaction was
higher than satisfaction with walking, but differences were
small.
3.4 Survey Non-Completers
A total of 635 BRCs were sent to individuals who had
participated only in the baseline survey and did not com-
plete the follow-up surveys despite multiple reminders. Of
these, 214 were returned; the demographics and clinical
characteristics of these patients were comparable with the
baseline group. Among those who returned the BRCs,
nearly half were patients who viewed dalfampridine-ER
treatment favorably, reporting either that they were
continuing to take the drug (47 %) or planned to initiate it
(2 %); the remainder consisted of individuals who had
discontinued (44 %) or did not plan to initiate treatment
(7 %).
4 Discussion
Step Together is the first program that provides insight into
the real-world perspectives and experiences of patients
who initiate dalfampridine-ER treatment for MS-related
walking impairment. Based on the results of the enrollees
who completed the follow-up surveys, patients perceived
that the impact of dalfampridine-ER treatment may extend
beyond improvement in walking and may include func-
tional improvements as manifested by less disruption of
their normal work, social, and daily activities. Notably,
improvement did not vary substantially with baseline
severity of walking impairment, as indicated by mMSWS-
12 scores. These results are consistent with reports from the
literature that showed that walking improvement among
patients treated with dalfampridine-ER was independent of
demographic variables, disease characteristics, and level of
disability [11, 19].
The response rates in the current program were similar
to those observed in other patient feedback surveys
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Fig. 2 Functional impairment to normal work, social life, and daily
activities as measured by the mSDS in the completers (n = 522).
aMean ± SD scores for baseline and follow-up periods. b Proportion
of patients reporting a high level of disruption (score of 7–9 on the
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in a parental survey that assessed the treatment effect of
lisdexamfetamine dimesylate for pediatric attention deficit
hyperactivity disorder, 29.5 % of the baseline participants
completed the 6-week follow-up survey [20], whereas,
23.2 % of the baseline survey participants completed both
follow-ups in the current program.
While the average magnitude of change in mMSWS-12
in the completer group exceeded 14 points in the follow-up
surveys, 68–74 % of patients achieved C4- and 6-point
changes that were considered as the MCID for this measure
[13]. These changes were observed at both follow-up
periods, as well as in all mMSWS-12 baseline quintiles.
Furthermore, improvements observed at the first follow-up
were maintained at the second follow-up. Both the mag-
nitude of change on the mMSWS-12 and the proportion of
patients achieving the MCID were greater in the current
program than the changes reported in the dalfampridine-ER
clinical studies. In the MS-F203 and MS-F204 studies,
35 and 42.9 % of those treated with dalfampridine-ER
were considered as timed-walk responders (placebo: 8 and
9.3 %, respectively), based on consistency of walking
speed improvement, as measured by T25FW. Timed-walk
responders, regardless of treatment assignment, showed
greater changes in MSWS-12 scores from baseline relative
to non-responders in both studies: -6.84 and -6.04 versus
-0.05 and -0.85 in MS-F203 and MS-F204, respectively
[9–11]. The results from these clinical trials were consis-
tent with improvements of approximately 11 points on the
MSWS-12 that have been reported in clinical practice [14,
15]. In particular, using a case series, Prugger and Berger
[15] reported higher proportions of patients as treatment
responders based on the response definition of MSWS-12
relative to the T25FW. Although in that study an MSWS-
12 responder was based on any improvement in MSWS-12
score, the magnitude of the improvement as reported by an
11-point change after 4 weeks of treatment among those
who remained on treatment was similar to that observed in
the current program. These observations suggest that
greater benefits can be obtained from patient-reported
outcome scales in the clinical practice relative to what may
be expected using clinician-assessed measures in clinical
trials. While it is also likely that bias is present in real-
world data, the reasons for this observed difference warrant
further investigation. The utility of patient-reported out-
comes for use in patients treated with dalfampridine is also
supported by two recent studies showing benefits in
domains of patient-reported quality of life [21, 22].
Overall satisfaction with treatment was consistently
higher than satisfaction with walking in all quintiles of
baseline impairment, although the differences were small.
This relatively greater overall satisfaction with treatment
than with walking suggests that patients treated with dal-
fampridine-ER might be perceiving benefits of treatment
that are not captured by walking assessments alone, a
possibility previously mentioned in the literature [23].
While quality of life has been assessed in people with MS,
the impact of dalfampridine-ER treatment on the functional
domains of work and social activities has not been previ-
ously reported. Thus, it is of interest to note that
improvements in mMSWS-12 scores were paralleled by
improvements in mSDS functional domains as indicated by
less disruption to normal work, social, and daily activities.
The impact of dalfampridine-ER treatment was further
strengthened by moderate to strong associations that were
observed at both follow-ups, suggesting that improvement
in walking may reflect in performance activities.
4.1 Limitations
This study reflects real-world utilization of dalfampridine-
ER and reports patient perspectives pertaining to treatment
outcomes. Such data are valuable for informing patients,
HCPs, and healthcare stakeholders regarding the clinical
expectations and outcomes that may be associated with
treatment beyond a controlled clinical trial setting.
However, there are several limitations to this analysis.
Participants enrolled in the program voluntarily; therefore,
selection bias may have been a factor, as patients who
completed all three surveys might be different from those
who did not. As with all such surveys from patient
feedback programs [24–26], the potential for selection
bias could arise as patients who had chosen to participate
might have had characteristics and outcomes different
from those who had not; no information is available on
patients who chose not to participate and therefore it was
not possible to determine the extent of selection bias that
may have impacted this analysis. Although the demo-
graphics and baseline severity of walking impairment
captured through BRCs were similar in completers and
non-completers, other relevant differences might exist
between these subgroups that have not been captured. To
reduce this bias, further studies should take into account
any potential differences in MS patients on dalfampridine-
ER who choose to enroll in the program versus those who
do not.
Because the survey was initiated to capture patient
perceptions on dalfampridine-ER treatment on walking in
order to facilitate communication with their HCPs, it
focused primarily on walking outcomes and this may have
limited the assessment of other treatment benefits. In
addition, the assessment was based on changes from
baseline; hence, there were no comparator groups in the
program design.
Another limitation is that, although the goal was to
follow up with the participants at 30 and 60 days after
treatment initiation, the actual duration on dalfampridine-
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ER among the survey respondents varied by ±2 weeks for
the first follow-up and by as much as 4 weeks for the
second follow-up. Thus, it cannot be ruled out that differ-
ences between those who responded early versus those who
responded late to either of the follow-ups may have
affected the results.
Patients had an equal opportunity to report negative and
positive responses to the treatment; nonetheless, the
responses were subjective and the extent to which patients
may have given socially desirable responses is not known.
Additionally, this program not only modified the instru-
ments from their existing forms, but also allowed for
completion of the survey by either telephone or Internet.
Neither the original MSWS-12 and SDS nor their modified
versions used in the current study have been validated for
administration via telephone or Internet, and these modi-
fications and methods of administration may also have
affected the results.
5 Conclusions
In this real-world survey, patients reported a clinically and
statistically significant association between dalfampridine-
ER treatment and walking improvement, as well as
improvements on normal work, social, and daily activities
compared with baseline. Patients who completed all three
surveys expressed moderate satisfaction with overall dal-
fampridine-ER treatment, and the majority indicated that
participating in the survey would help them communicate
better with their HCPs. Notwithstanding the limitations of
this survey, the results highlight the utility of patient-
reported outcome scales in the assessment of patient per-
spective and experience, providing a useful supplement to
traditional objective measures used in clinical studies and
practice.
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